It has been observed that selective COX-2 inhibitors can affect the checkpoints in the cell cycle by reducing the levels of cyclin D1 and cyclin E. Therefore, CDK2 and COX-2 are potential targets for cancer treatment [87,88]. Here, PTGS2 is linked to cancer.